Figure 1 (Ruxience 01)
Ruxience Injection, Solution
Product Images NDC 0069-0249
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ruxience (NDC 0069-0249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Ruxience 02)
The text represents a graph showing the percentage of patients who achieved an ACR20 response, with the X-axis showing the number of weeks and the Y-axis representing the percentage of patients. The graph includes two lines, one for a group that received placebo treatment and one for a group that received treatment with Rituximab 2x1000mg. The graph shows that a higher percentage of patients in the Rituximab group achieved an ACR20 response compared to the placebo group at each week's interval.*
Logo (Ruxience 03)
Logo (Ruxience 04)
This product is a biosimilar and is distributed by Pfizer Labs which is a division of Pfizer Inc. based in New York City with the zip code 10017.*
Principal Display Panel (10 mL Vial Label)
Principal Display Panel (10 mL Vial Carton)
Description: This is the label of a medicine called Ruxience (rituximab-pvvr) Injection, with a dosage of 100mg/10mL, to be diluted and used intravenously. It includes instructions to refrigerate the vial at 2 to 8 degrees Celsius, and not to freeze or shake it. There is a warning to discard the unused portion, and to dispense the enclosed medication guide to each patient, with prescribing information. The manufacturer is Pfizer Ireland Pharmaceuticals, Cork.*
Principal Display Panel (50 mL Vial Label)
Ruxience is a type of rituximab, which is administered by injection. The package comes with one preservative-free, 100mg single-dose vial, which each milliliter of the solution containing 10mg of rituximab, L-histidine, edetate disodium dihydrate, L-histidine hydrochloride monohydrate, water for injection, USP, polysorbate 80, and sucrose. Ruxience is stored in a cool dry place between 2-8°C (36-46°F) and comes with instructions for dosing and dilution. Only use the medication guide included with the package. There's no US standard of potency.*
Principal Display Panel (50 mL Vial Carton)
This is a medication called LoTEXP, which comes in a single dose vial and is used according to the prescribing information for dosing and dilution instructions. The medication has no preservative and must be stored refrigerated (2°C to 8°C) in the carton to avoid direct sunlight, and cannot be frozen or shaken. The medication is manufactured by Pfizer Ireland Pharmaceuticals and comes with a medication guide enclosed. The NDC number for this medication is 0069-0249-01 and is to be injected only once, with unused portions to be discarded.*
Ruxience 09
This text appears to be a description of a medication called Ruxience, which is an injection used for intravenous use. The medication guide includes instructions for each patient and advises them to discard any unused portion. The medication is available in a single-dose vial and does not contain any preservatives. The text also includes manufacturing and contact information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
